Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities to reduce CV events, Frederik Persson discusses future possibilities for use of GLP-1RA. With question to test your knowledge.
Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.
There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD. With question to test your knowledge.
What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video. With question to test your knowledge.
Ofri Mosenzon discusses the importance of identification of CKD and how to prevent CKD progression in T2DM with older and newer therapeutic options. With question to test your knowledge.
Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.
ERA-EDTA 2021 Prof. Wanner presents the results of a post hoc analysis of EMPA-REG OUTCOME, in which potential mediators of the treatment effect of empagliflozin on kidney outcomes were explored.
The predictive performance of six risk scores for ischemic stroke in patients with AF and CKD were validated. The Modified CHADS2 score showed good performance for discrimination and calibration in all kidney function categories.
Prof. Januzzi talks about the biology of natriuretic peptides and discusses their performance in patients with kidney disfunction for diagnosis and prognosis of HF.
Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.
A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.
A post hoc analysis of patients in the CREDENCE trial with baseline eGFR <30 mL/min/1.73 m² was performed. Prof. Bakris shares the results of this analysis.
AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.
Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.
ESC 2020 After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.
Recent CVOTs with GLP-1RAs included kidney outcomes as a secondary endpoint. Johannes Mann presents kidney results of these trials and raises questions from a nephrologist's perspective.
Prof. Wanner presents a case of a CKD patient who has developed diabetes. He discusses what the optimal treatment strategy for such a patient is and how new treatments have resulted in a paradigm shift in nephrology.
Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.
Maria Rosa Constanzo explains the function of SGLT2 in the early proximal tubule of the kidney in detail and discusses how blockade of SGLT2 may result in beneficial effects.
ERA-EDTA 2020 The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.
Prof. Mark Cooper gives an overview of older glucose lowering therapies and more recent newer treatment options, with a focus on SGLT2 inhibitors, and their effect on kidney outcomes in CKD and DKD patients. With question
AHA 2019 The ISCHEMIA-CKD trial evaluated whether there is a benefit of adding coronary angiogrpahy and revascularization to OMT in patients with advanced CKD and at least moderate ischemia.
Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.
Alkaline phosphatase (ALP) is a potential novel treatment target for CVD in CKD. Dr. Haarhaus discusses ALP-related mechanisms of increased CV risk and beneficial effects of the BET inhibitor apabetalone.
Paola Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.
Dr. Herrington summarizes key randomized data from completed large placebo-controlled SGLT2-inhibitor trials and describes ongoing SGLT2i trials in diabetes, renal and HF populations.
Frederik Persson shows evidence of renoprotective effects with GLP-1RA treatment, by discussing various small clinical trials as well as CVOTs with GLP-1RAs.
Epigenetic processes are involved in renal damage. Marta Ruiz-Ortega describes the role of vascular calcification and alkaline phosphatase (ALP) in CKD and effects of BET inhibition on vascular calcification.
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the management of CKD with resistant hypertension.
Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.
ERA-EDTA 2019 Epigenetics contribute to vascular calcification, which is a hallmark of CVD in CKD. Prof. Brandenburg explains how BET inhibition can interfere with factors and pathways associated with vascular calcification.
ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.
ESC HF 2019 Prof. Rossignol talks about the AMBER trial and a prespecified analysis of HF patients. Patiromer use resulted in higher spironolactone maintenance in patients with resistant hypertension and CKD.
ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.
ISN-WCN 2019 Use of canagliflozin in T2DM patients with kidney disease resulted in reduction of renal and CV outcomes, irrespective of baseline kidney dysfunction. Prof Carol Pollock discusses the results of the CREDENCE trial.
ISN-WCN 2019 Prof. Hiddo Lambers Heerspink dissusses the unique design of the SONAR trial and the findings with atrasentan therapy in patients with diabetic kidney disease.
ISN-WCN 2019 The SONAR trial was designed to safely test the effect of atrasentan in a selected group of high-risk T2DM patients with kidney disease. This proved to be a good approach, as results were very positive.
ICN-WCN 2019 Prof. Perkovic summarizes the results of the CREDENCE trial that tested the SGLT2 inhibitor canagliflozin. It is a safe drug that prevents kidney failure and CV complications in people with diabetes and kidney disease.
Cardio Diabetes Masterclass Dubai Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits .
Cardio Diabetes Masterclass Dubai Prof. Montanya discusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trial, respectively.
Kalantar shares data that suggest that epigenetic modification with the BET inhibitor apabetalone may improve factors involved in the pathogenesis of CKD, including alkaline phosphatase.
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CKD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.
Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.
Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.
Prof Baigent discusses the key areas of uncertainty of treatment with SGLT2 inhibitors in patients with CKD and what ongoing trials will likely contribute to our understanding of this drug class.
Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.
Louise Nordfors describes several epigenetic mechanisms that have been described to be dysregulated in human disease and the rationale for BET protein inhibition to treat CV and renal disease.
ACC 2018 A new analysis of the CANTOS trial showed that IL-1β inhibition in patients with stage 3 kidney disease did not slow progression to renal failure, but did beneficially alter outcomes in these very high risk patients.
Prof. Neil Poulter gives an overview of a subgroup analysis of the LEADER trial in which patients with CKD treated with liraglutide showed a reduction of CV events as compared with those on placebo treatment.
Kamyar Kalantar-Zade, MD shows the data based on which alkaline phosphatase is emerging as a prognostic biomarker of CV events. BET inhibition with apabetalone lowers ALP, and may thus be a promising therapeutic strategy.
Luis M Ruilope, MD looks at the evidence showing that currently available therapies leave room for improvement in the reduction of CV events in patients with diabetes and chronic kidney disease.
Prof. George Bakris, MD, recommends to balance the benefit of BP-lowering on the heart and the kidney in older people. BP control is vital to slow progression of CKD, but a too low BP can be harmful.
Dr. Per-Henrik Groop outlines that diabetic kidney disease is common and associated with a grim prognosis. Optimal glucose control is central to limiting the risk of renal complications. Newer antidiabetic drugs can play a welcome role to optimally treat these patients.
Very recently, data became available of use of the SGLT2-inhibitor empagliflozin in patients with diabetic kidney disease, a condition associated with increased risk of CV complications. Prof. Groop shares the data that suggest that empagliflozin can reduce or prevent the onset of this condition.
Dr Horst Sievert, Germany, highlights current status of catheter based techniques to treat resistant hypertension.
Dr Christina Reith, Oxford about new insights from the SHARP and its implications for clinical practice
Prof. John Cunningham (London, United Kingdom) discusses what are the responses to a decrease of GFR on kidney disease and how these can be triggered.
Prof. Denis Fouque (Lyon, France) discusses the role of protein intake on renal function and on phosphate levels.
In this expert opinion prof. Guntram Schernthaner discusses the optimal target value of HbA1c, in diabetes or if combined with cardiovascular disease or renal impairment.
Prof Jane Armitage, Oxford discusses the results and the implications of the Study of Heart and Renal Protection (SHARP ) with prof John Betteridge London, UK.